KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kymera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$108.07+3.29 (+3.14%)
Close on Oct 19, 2026
- Market cap
- $10.61B
- P/E (TTM)
- –
- Dividend yield
- –
Kymera Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Market Cap | $8.99B | $164.85M |
| Enterprise Value | $8.30B | $87.06M |
| PS Ratio | 85.58 | 3.60 |
| PB Ratio | 5.95 | 2.03 |
| P/TBV Ratio | 5.95 | 2.31 |
Enterprise value
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 79.00 | 2.43 |
Income (trailing twelve months)
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Revenue | $105.00M | $57.94M |
| Gross Profit | $0 | $90.47M |
| Operating Income | -$350.18M | -$21.44M |
| Net Income | -$299.60M | -$22.46M |
| EBITDA | -$341.95M | -$16.91M |
| EPS (Diluted) | -$3.24 | -$0.83 |
Margins
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 0.00% | 52.3% |
| Operating Margin | -333.5% | -44.5% |
| Profit Margin | -285.3% | -39.2% |
| EBITDA Margin | -325.7% | -31.3% |
| FCF Margin | -226.6% | -8.85% |
Returns
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -24.2% | -53.1% |
| Return on Assets (ROA) | -21.6% | -41.0% |
| Return on Invested Capital (ROIC) | -49.2% | -32.0% |
| Return on Capital Employed (ROCE) | -22.2% | -37.8% |
Growth
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 134.8% | 6.01% |
| Revenue Growth (3Y CAGR) | -5.74% | 2.25% |
| Revenue Growth (5Y CAGR) | 2.87% | 6.42% |
Balance sheet
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $690.99M | $62.42M |
| Net Cash (Debt) | $690.99M | $15.68M |
| Net Cash Per Share | $8.31 | $0.66 |
| Equity (Book Value) | $1.51B | $48.79M |
| Book Value Per Share | $18.15 | $1.36 |
| Tangible Book Value | $1.51B | $23.06M |
| Working Capital | $665.94M | $75.77M |
Financial position
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 10.34 | 3.30 |
| Quick Ratio | 9.97 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$236.76M | -$12.35M |
| Capital Expenditures | -$1.19M | -$1.06M |
| Free Cash Flow | -$237.96M | -$20.28M |
| FCF Per Share | -$2.86 | -$0.42 |
Efficiency
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.08 | 0.38 |
| Revenue Per Employee | $441.17K | $398.96K |
| Profits Per Employee | -$1.26M | -$703.34K |
| Employee Count | 238 | 74 |
Dividends and yields
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -3.33% | -22.7% |
| FCF Yield | -2.65% | -9.07% |
Shares
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 83,150,600 | 58,179,650 |
| Shares Change (YoY) | 17.7% | 11.1% |
| Shares Change (QoQ) | 0.74% | 0.54% |
| Float | 50,417,600 | 49,173,100 |
| Shares Held by Insiders | 39.4% | 11.6% |
| Shares Held by Institutions | 116.7% | 59.4% |
Scores
| Measure | Kymera Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 38.42 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Kymera Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.